Effectiveness of deguelin on in vitro anti-cancer Marker in pancreas and prostate cancers

OBJECTIVES : Pancreatic cancer is a widely diagnosed cancer type with very poor prognosis worldwide. Prostate carcinoma is the most common malignant tumor in males of Western countries. Androgen-independent prostate cancer is highly metastatic and therefore resistant to both chemotherapy and radiation. The aim of this study is to compare the efficacy of standardized Gemcitabine and Deguelin, which is used firstly in the treatment of pancreatic cancer, and to compare the efficacy of Docetaxel and Deguelin, which are used first in prostate Ca standard therapy, and to evaluate invasion and metastasis responses. MATERIALS-METHODS : In this study we examined the anticancer effect of Deguelin on pancreatic cancer cell line PANC-1 and prostate cancer cell lines PC-3 and DU-145. For this purpose, cell viability tests were performed to determine the preventive effects of Docetaxel, Gemcitabine and Deguelin on the PC-3, DU-145 and PANC-1 cell lines and to determine the relative effective dose. The determined effective concentrations were applied to the cells in different drug combinations and cell cycle, apoptosis, migration and angiogenesis analyzes were performed using flow cytometry. RESULTS: Deguelin was found to be effective in PANC-1 cell line at very low concentrations and not being effective in prostate cancer lines. CONCLUSIONS: In the light of the results, It was determined that this effect was due to the difference in carcinogenesis stages of two different invasive organ cancers, and it would be important to identify the details with advanced pathway studies.